Top 3 Medical Uses of Placental Stem Cells

Placental stem cells are being studied most for wound repair, heart damage, and immune-related disease. The short version: they may help calm inflammation, support new blood vessel growth, and send repair signals after injury.

Here’s the plain-English takeaway:

• Wound healing: already tied to some FDA-cleared placental graft products, while lab-grown placental stem cell treatments are still in trials
• Heart disease: being studied for heart attack damage, scar reduction, and pump function, but still mostly in animal research and early human studies
• Autoimmune disease: being tested for conditions driven by immune overreaction, but there are no FDA-approved placental stem cell treatments in this area

A few numbers stand out:

• About 3.5 million placentas are delivered in the U.S. each year
• One placenta can yield around 500 million different types of stem cells
• A 2025 Phase 2 trial reported 38.5% ulcer closure vs. 22.6% with placebo in diabetic foot ulcers
• Nearly 40 completed trials have studied placental tissue-derived MSCs

Quick Comparison

Use area	What doctors are targeting	Main idea behind use	Where it stands now
Wound repair	Diabetic foot ulcers, burns, venous ulcers, eye surface defects	Help tissue close, limit infection, and support repair	Some placental grafts in use; isolated cells still experimental
Heart damage	Heart attack injury, heart failure, poor blood flow	Support blood vessel growth, reduce scar, and help heart function	Mostly preclinical; early human research
Autoimmune disease	GvHD, Crohn’s disease, MS, RA, lupus	Calm immune attack and reduce inflammation	Early clinical trials only; no approved therapies

If you want the simple answer, it’s this: placental stem cells look most useful where healing depends on less inflammation and better repair signaling.

Why Placental Stem Cells Are Getting Medical Attention

The main reasons come down to biology.

Placental MSCs are multipotent, release growth factors and anti-inflammatory signals, and are less likely to trigger rejection. That helps explain why placental stem cells are being studied most often for tissue repair, cardiovascular injury, and immune disease, which is why many parents choose to bank placental tissue.

Their low immunogenicity also makes them useful across different patients. In plain English, the cells are less likely to set off the kind of immune reaction that can get in the way of treatment.

They can also shift the immune response away from inflammation and toward repair. That mechanism matters in several of the conditions covered below, especially when healing depends on calming damage before the body can start rebuilding.

Some uses, such as certain wound and eye grafts, are already regulated for clinical use. Others are still in clinical trials. Put together, those traits make placental stem cells most relevant in wound healing, heart injury, and autoimmune disease.

1. Wound Healing and Tissue Repair

The Target Condition

Chronic wounds - especially diabetic foot ulcers, venous leg ulcers, pressure sores, and severe burns - are a major health issue. They affect about 8.2 million Medicare patients each year and cost up to $96.8 billion annually.

Researchers study placental tissue here for a simple reason: wounds need the right raw materials to close, and placental tissue contains many of those parts.

Why Placental Stem Cells Are Studied for This

Placental tissue contains growth factors, antimicrobial peptides, and extracellular matrix proteins that support repair. It also has a low rejection risk, which makes donor-to-patient use more feasible.

That mix helps explain why researchers keep coming back to it. The goal isn’t magic. It’s to support the basic steps the body already uses to repair damaged tissue.

Proposed Therapeutic Effects

Researchers are looking at how these cells and their secreted factors may help with:

• new blood vessel growth
• skin-cell migration
• tissue repair
• limiting infection
• reducing scarring

Antimicrobial peptides matter here too. They may help hold back infection, which is often one of the biggest reasons a wound stalls instead of healing.

Current Research Status

Amniotic membrane grafts are FDA-cleared for certain wound uses. But isolated, expanded placental stem cells are still experimental.

In a 2025 Phase 2 trial with 159 participants, placenta-derived cells led to a 38.5% complete ulcer-closure rate versus 22.6% with placebo in patients with diabetic foot ulcers and poor circulation.

Those same repair signals are also being studied in tissue damage tied to poor blood flow, including heart disease.

2. Heart Disease and Ischemic Injury

The Target Condition

Like chronic wounds, ischemic heart damage comes down to two big problems: getting blood flow back and keeping inflammation in check.

Cardiovascular disease is still a major clinical challenge. When blocked blood flow causes heart tissue to die, the body doesn't rebuild that lost muscle. Instead, it replaces it with scar tissue. That scar can help hold the heart together, but it doesn't contract like healthy heart muscle. Over time, that can weaken how well the heart pumps.

That's why researchers are studying placental stem cells as a possible way to deal with damage that the body can't reverse on its own.

Why Placental Stem Cells Are Studied for This

Placental cells are being studied here for a few reasons. Some appear able to move toward injured heart tissue after delivery. One placental cell subset has shown the ability to selectively home to damaged cardiac tissue when given intravenously, then differentiate into beating heart muscle cells and vascular cells.

These cells also release growth factors that can support new blood vessel formation in low-oxygen tissue. In plain terms, they may help the injured heart in more than one way: by going to the damaged area, by turning into useful cell types, and by sending signals that support repair.

Another point researchers pay close attention to is their low immune activity. That makes off-the-shelf use more realistic than it is with many other cell types.

Proposed Therapeutic Effects

Researchers are focusing on three main effects.

• Placental cells and their exosomes may reduce the size of the damaged area after a heart attack
• They may limit scarring that can feed into heart failure
• They may improve pumping function

That sounds promising on paper, but the big issue is whether these effects hold up in practice. Animal studies and early clinical reports are now testing whether those mechanisms lead to actual cardiac repair.

Current Research Status

Right now, this field is still mostly preclinical, with only limited early clinical use.

In a 2019 study published in PNAS, Dr. Chaudhry's team showed that intravenous placental cells in a mouse model of myocardial infarction differentiated into functional heart muscle and blood vessels. MRI also confirmed improved cardiac contractility and overall heart function.

As of 2026, placental stem cell therapies for heart disease remain unapproved outside research and limited surgical use.

The same anti-inflammatory effect also matters in autoimmune disease, where the immune system drives the injury.

3. Autoimmune and Inflammatory Disorders

The Target Condition

Placental stem cells aren't only being looked at for injured tissue. They're also being studied in autoimmune and inflammatory disorders, where the immune system goes off track and starts attacking healthy tissue.

That includes conditions like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), and Crohn's disease. These diseases share a common problem: persistent immune activity and inflammation. So the main focus of this line of research is immune regulation.

Why Placental Stem Cells Are Studied for This

One big reason researchers keep looking at placental mesenchymal stem cells is that they appear less likely to set off rejection when used from a donor to a patient.

But that's only part of the story. Researchers are also studying whether these cells can dial down an overactive immune response and help push the body toward repair. In Crohn's disease, for example, they're being examined for their potential to reduce intestinal inflammation and help repair the gut barrier.

Current Research Status

This field is still in its early stages. Most uses are still in preclinical research or Phase 1/2 clinical trials.

One Phase 1/2 trial looked at severe acute GvHD. In that study, 21 patients received DP-MSCs. All responded by day 28, and 11 had complete resolution. The study also reported an 81% 1-year survival rate and a 57% 4-year survival rate.

At this point, there are no FDA-approved placental stem cell therapies for autoimmune disorders.

Side-by-Side Look at the 3 Use Areas

These three uses sit at different points in development. And while the same low-rejection profile and repair signals show up in all of them, they play out in different ways depending on the condition being treated.

Use Area	Target Conditions	Why Placental Stem Cells May Help	Evidence Status
Wound Healing & Tissue Repair	Burns, diabetic foot ulcers, venous ulcers, corneal defects	Provides scaffold support and growth factors that aid skin repair.	Clinically used for some grafts; isolated expanded cells remain experimental.
Heart Disease & Ischemic Injury	Myocardial infarction, heart failure, critical limb ischemia, peripheral arterial disease	Promotes new vessel growth, limits fibrosis, and supports heart function.	Mainly preclinical; early clinical trials underway.
Autoimmune & Inflammatory Disorders	GvHD, multiple sclerosis, type 1 diabetes, Crohn's disease	Calms overactive immune cells and shifts inflammation toward repair.	Early clinical research; no approved uses.

Across all three areas, the main effect appears to come from the signals these cells release, not only from turning into replacement cells. That matters. It suggests the value may lie less in direct tissue swap-out and more in how the cells help the body repair itself.

Another thread runs through all three categories: low immune rejection risk. Because placental tissue naturally supports immune tolerance during pregnancy, researchers see these cells as a strong fit for allogeneic transplants, with a lower chance of rejection than many other cell sources. The target tissues may change, but the core idea stays the same - repair signaling plus a lower-risk immune profile.

The next section explains what still keeps these uses from broader clinical adoption.

Research Status and Current Limits

Placental stem cell therapy has shown promise, but it’s still in the early stages. In the U.S., most uses of placental stem cells are still investigational. Right now, only some acellular placental membrane products are used in routine wound care and eye care.

The FDA makes a sharp distinction here. If placental membrane is used in acellular form as a covering, it falls under the FDA’s less restrictive tissue rule. But if placental tissue is grown or processed for regenerative use, things change fast. It must go through IND review and biologics approval before human trials can start.

That line matters because it shows where the field stands today: part of it is already in medical use, while the cell-based side is still moving through the research pipeline.

Nearly 40 completed trials have looked at MSCs derived from placental tissue. That’s real progress. At the same time, it also makes one thing plain: these therapies are not standard care yet.

There are also scientific limits that haven’t been sorted out. Cells differ depending on where they come from. For example, cells from fetal placental tissue tend to grow faster and suppress immune activity more strongly than maternal-source cells. On top of that, standardized dosing protocols for systemic diseases still haven’t been set, and long-term outcomes from allogeneic transplants remain largely unknown.

Access adds another layer of difficulty. Placental tissue has to be collected soon after birth, which leaves little room for delay. In many U.S. hospitals, the placenta is discarded unless parents make plans ahead of time, such as through a private banking service like Americord Registry. And timing is tight: placental tissue usually needs to be processed within about 6 hours of delivery to remain viable.

Conclusion

These uses all point back to the same strengths: repair support, vascular signaling, and immune control.

Placental stem cells look most promising for wound repair, ischemic injury, and immune-driven disease because they pair growth-factor signaling with low immunogenicity. Most uses are still investigational, but early studies keep supporting their place in regenerative medicine.

For families interested in banking placental tissue, Americord Registry offers placental tissue banking. Their value comes from the way they support healing, blood flow, and immune balance.

FAQs

Are placental stem cells the same as placental grafts?

No. Placental stem cells and placental grafts are related, but they are not the same.

Placental tissue contains stem cells, growth factors, and cytokines. A placental graft usually refers to the placental membrane, often the amniotic layer, used as a biological dressing or surgical implant.

Put simply, one term points to what’s in the tissue, while the other points to how the tissue is used in care. A placental graft describes the tissue’s clinical use as a protective, regenerative barrier.

Why are wound treatments further along than heart or autoimmune uses?

Wound treatments for burns, ulcers, and eye injuries are further along because they mostly use placental tissue as a biological dressing or physical scaffold.

That local use gives the tissue a direct job: it covers and protects the damaged area while delivering growth factors and cytokines right where they’re needed. In plain terms, it acts a bit like a protective layer that also helps the body repair itself, which can support faster healing and less scarring.

Heart and autoimmune uses are tougher. They depend on more complex whole-body integration or very specific cell differentiation, and both are still under study.

What needs to happen before placental stem cell therapies become standard care?

Placental stem cell therapies still need to move through clinical trials to clearly confirm their safety and effectiveness.

Right now, placental tissue already has FDA approval for surgical use as a biological dressing for wounds and burns. But uses beyond that have not yet received FDA approval.

That matters. There’s a big difference between early promise and approved medical use.

Researchers are now studying these cells for systemic diseases, and Americord Registry supports that path through placental tissue banking.